aibio
Financings ·
Molecular Partners prices $20 million offering of 3,642,988 ADSs at $5.49
The Swiss company plans to use the money for its radiopharmaceutical pipeline and working capital. Leerink Partners and TD Cowen are joint bookrunners.
MOLN Molecular Partners AG
Molecular Partners (MOLN) news MOLN offering news
Latest Molecular Partners news
We have not published a story on Molecular Partners yet. When there is news, it will appear here.
What Molecular Partners does
Molecular Partners AG is a clinical-stage biotechnology company that designs and develops DARPin therapeutics, a class of custom-built protein drug candidates based on natural binding proteins. Its programs are at various stages of preclinical and clinical development, with a main focus on oncology. The lead candidate, MP0712, is a Radio-DARPin targeting DLL3 for SCLC and other neuroendocrine cancers. It is in a Phase 1/2a trial in the United States and is co-developed with its strategic partner Orano Med. Other programs include MP0726, a Radio-DARPin targeting MSLN, and MP0533, a tetra-specific T-cell engaging DARPin for AML and high-risk MDS, which is in a Phase 1/2a trial. MP0317, a FAP-localized CD40 agonist, is in an investigator-initiated Phase 2 trial with standard-of-care for cholangiocarcinoma. The company also has a CD3 Switch-DARPin T cell engager program. The text says its DARPin candidates have been tested in more than 2,500 patients. The co-development agreement with Orano Med includes up to ten potential oncology candidates.
| Product or program | What it is | Stage |
|---|---|---|
| MP0712 | Radio-DARPin targeting DLL3 for SCLC and other neuroendocrine cancers | Phase 1/2a in the United States |
| MP0726 | Radio-DARPin targeting MSLN | in development, toward first-in-human imaging |
| MP0533 | Tetra-specific T-cell engaging DARPin for AML and high-risk MDS | Phase 1/2a |
| MP0317 | FAP-localized CD40 agonist used with standard-of-care for cholangiocarcinoma | investigator-initiated Phase 2 |
| CD3 Switch-DARPin T cell engager | Logic-gated T cell engager program led by a lead candidate selection |
Molecular Partners annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | CHF 5.0 million | |
| Research and development | CHF 40.2 million | CHF 48.6 million |
| Net income (loss) | -CHF 61.7 million | -CHF 54.0 million |
| Cash from operations | -CHF 51.3 million | -CHF 59.2 million |
| Cash and equivalents | CHF 82.7 million | CHF 63.9 million |
Questions about Molecular Partners
Has Molecular Partners raised money recently?
Our latest story on this, dated Oct 28, 2024: "Molecular Partners prices $20 million offering of 3,642,988 ADSs at $5.49". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Molecular Partners?
Molecular Partners AG trades under the ticker MOLN on SIX.
Where is Molecular Partners listed?
Molecular Partners AG is listed on SIX. Our directory also records these other listings: BX:6ML; GETTEX:6ML; LS:A12DEH; LSE:0QXX; NASDAQ:MOLN.
What is the SEC CIK of Molecular Partners?
The SEC Central Index Key (CIK) for Molecular Partners AG is 1745114. Its filings are on SEC EDGAR.
How many shares does Molecular Partners have outstanding?
40,374,641 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-12.
Which country or territory is Molecular Partners listed under?
Our directory records Molecular Partners AG under Switzerland.
What does Molecular Partners do?
Our directory classifies Molecular Partners AG as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Molecular Partners?
The ISIN recorded for Molecular Partners AG is CH0256379097.
Does aibio.space cover Molecular Partners?
aibio.space lists Molecular Partners AG among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Molecular Partners incorporated?
SEC records list its state or country of incorporation as V8.
What does Molecular Partners develop?
Molecular Partners AG is a clinical-stage biotechnology company that designs and develops DARPin therapeutics, a class of custom-built protein drug candidates based on natural binding proteins. Its programs are at various stages of preclinical and clinical development, with a main focus on oncology.
What is MP0712 from Molecular Partners?
MP0712: Radio-DARPin targeting DLL3 for SCLC and other neuroendocrine cancers Stage: Phase 1/2a in the United States.
What is MP0726 from Molecular Partners?
MP0726: Radio-DARPin targeting MSLN Stage: in development, toward first-in-human imaging.
What is the latest Molecular Partners (MOLN) stock news?
Our latest story on Molecular Partners, dated Oct 28, 2024: "Molecular Partners prices $20 million offering of 3,642,988 ADSs at $5.49". The Swiss company plans to use the money for its radiopharmaceutical pipeline and working capital. Leerink Partners and TD Cowen are joint bookrunners. Source.
Is Molecular Partners a smaller reporting company?
SEC records list Molecular Partners AG's filer category as: Non-accelerated filer<br>Emerging growth company.
Investor discussion: Molecular Partners
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Stock chart
SEC filings and registration
- SEC name
- Molecular Partners Ag
- CIK
- 1745114
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- MOLN (Nasdaq)
- State or country of incorporation
- V8
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Business address
- WAGISTRASSE 14, Schlieren-Zurich, Switzerland, 8952
- Phone
- 41 44 755 77 00
- Shares outstanding
- 40,374,641 as of 2025-12-31 (20-F filed 2026-03-12)
Recent filings
Listing details
- Company
- Molecular Partners AG
- Ticker
- MOLN
- Listing
- SIX
- Country or territory
- Switzerland
- Business scope
- Biotechnology
- ISIN
- CH0256379097
- Other listed symbols
- BX:6ML; GETTEX:6ML; LS:A12DEH; LSE:0QXX; NASDAQ:MOLN
- Last quote in directory
- 2026-10-22
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction